

Herantis Pharma to Participate in Investor and Partnering Conferences

Herantis Pharma Plc, Press Release, 2 May 2022 at 11:15 EEST

Herantis Pharma Plc (“Herantis”), developing disease modifying therapies for Parkinson’s disease, today announced that members of the Herantis management team will be attending and holding 1x1 meetings with investors and pharmaceutical companies at the following conferences:

Nordic Health Summit Japan (Virtual)

Herantis will participate in the Nordic Pitch Showcase session.

1x1 meetings will be scheduled during May 11-13, 2022

Inderes Investment Day May 23, 2022

The presentation will be available on May 23, 2022 in the service of Inderes (www.inderes.fi)

BioEquity Europe 2022 (Virtual)

The presentation will be live on the BioEquity Europe platform.

1x1 meetings will be scheduled during May 23-24, 2022

The presentations will be available via digital libraries, which are accessible to event participants only.

Please contact the conference organizers, or send an email to ir@herantis.com, if you wish to schedule a meeting with Herantis.

For more information, please contact:

Julie Silber/Gabriela Urquilla

Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email: ir@herantis.com

Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400

Company website: www.herantis.com

About Herantis Pharma Plc

Herantis Pharma Plc is an innovative biotech company developing disease modifying therapies for Parkinson’s Disease. Herantis lead product HER-096, is an advanced small and synthetic chemical peptidomimetic version of the active parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the ability to be delivered to the brain via subcutaneous administration.

The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information, please visit <https://www.herantis.com>